BACKGROUND: Hypochromic microcytic anemia associated with ineffective erythropoiesis caused by recessive mutations in divalent metal transporter 1 (DMT1) can be improved with high-dose erythropoietin supplementation. The aim of this study was to characterize and compare erythropoiesis in samples from a DMT1-mutant patient before and after treatment with erythropoietin, as well as in a mouse model with a DMT1 mutation, the mk/mk mice. DESIGN AND METHODS: Colony assays were used to compare the in vitro growth of pre-treatment and post-treatment erythroid progenitors in a DMT1-mutant patient. To enable a comparison with human data, high doses of erythropoietin were administered to mk/mk mice. The apoptotic status of erythroblasts, the expression of anti-apoptotic proteins, and the key components of the bone marrow-hepcidin axis were evaluated. RESULTS: Erythropoietin therapy in vivo or the addition of a broad-spectrum caspase inhibitor in vitro significantly improved the growth of human DMT1-mutant erythroid progenitors. A decreased number of apoptotic erythroblasts was detected in the patient's bone marrow after erythropoietin treatment. In mk/mk mice, erythropoietin administration increased activation of signal transducer and activator of transcription 5 (STAT5) and reduced apoptosis in bone marrow and spleen erythroblasts. mk/mk mice propagated on the 129S6/SvEvTac background resembled DMT1-mutant patients in having increased plasma iron but differed by having functional iron deficiency after erythropoietin administration. Co-regulation of hepcidin and growth differentiation factor 15 (GDF15) levels was observed in mk/mk mice but not in the patient. CONCLUSIONS: Erythropoietin inhibits apoptosis of DMT1-mutant erythroid progenitors and differentiating erythroblasts. Ineffective erythropoiesis associated with defective erythroid iron utilization due to DMT1 mutations has specific biological and clinical features.
BACKGROUND:Hypochromic microcytic anemia associated with ineffective erythropoiesis caused by recessive mutations in divalent metal transporter 1 (DMT1) can be improved with high-dose erythropoietin supplementation. The aim of this study was to characterize and compare erythropoiesis in samples from a DMT1-mutant patient before and after treatment with erythropoietin, as well as in a mouse model with a DMT1 mutation, the mk/mk mice. DESIGN AND METHODS: Colony assays were used to compare the in vitro growth of pre-treatment and post-treatment erythroid progenitors in a DMT1-mutant patient. To enable a comparison with human data, high doses of erythropoietin were administered to mk/mk mice. The apoptotic status of erythroblasts, the expression of anti-apoptotic proteins, and the key components of the bone marrow-hepcidin axis were evaluated. RESULTS:Erythropoietin therapy in vivo or the addition of a broad-spectrum caspase inhibitor in vitro significantly improved the growth of humanDMT1-mutant erythroid progenitors. A decreased number of apoptotic erythroblasts was detected in the patient's bone marrow after erythropoietin treatment. In mk/mk mice, erythropoietin administration increased activation of signal transducer and activator of transcription 5 (STAT5) and reduced apoptosis in bone marrow and spleen erythroblasts. mk/mk mice propagated on the 129S6/SvEvTac background resembled DMT1-mutant patients in having increased plasma iron but differed by having functional iron deficiency after erythropoietin administration. Co-regulation of hepcidin and growth differentiation factor 15 (GDF15) levels was observed in mk/mk mice but not in the patient. CONCLUSIONS:Erythropoietin inhibits apoptosis of DMT1-mutant erythroid progenitors and differentiating erythroblasts. Ineffective erythropoiesis associated with defective erythroid iron utilization due to DMT1 mutations has specific biological and clinical features.
Authors: Victor R Gordeuk; Galina Y Miasnikova; Adelina I Sergueeva; Xiaomei Niu; Mehdi Nouraie; Daniel J Okhotin; Lydia A Polyakova; Tatiana Ammosova; Sergei Nekhai; Tomas Ganz; Josef T Prchal Journal: Blood Date: 2011-08-29 Impact factor: 22.113
Authors: Toshihiko Tanno; Prashanth Porayette; Orapan Sripichai; Seung-Jae Noh; Colleen Byrnes; Ajoy Bhupatiraju; Y Terry Lee; Julia B Goodnough; Omid Harandi; Tomas Ganz; Robert F Paulson; Jeffery L Miller Journal: Blood Date: 2009-05-04 Impact factor: 22.113
Authors: John B Porter; Patrick B Walter; Lynne D Neumayr; Patricia Evans; Sukhvinder Bansal; Maciej Garbowski; Marcela G Weyhmiller; Paul R Harmatz; John C Wood; Jeffery L Miller; Colleen Byrnes; Guenter Weiss; Markus Seifert; Regine Grosse; Dagmar Grabowski; Angelica Schmidt; Roland Fischer; Peter Nielsen; Charlotte Niemeyer; Elliott Vichinsky Journal: Br J Haematol Date: 2014-09-11 Impact factor: 6.998
Authors: J Stetka; P Vyhlidalova; L Lanikova; P Koralkova; J Gursky; A Hlusi; P Flodr; S Hubackova; J Bartek; Z Hodny; V Divoky Journal: Oncogene Date: 2019-04-09 Impact factor: 9.867
Authors: Katarina Kapralova; Ondrej Jahoda; Pavla Koralkova; Jan Gursky; Lucie Lanikova; Dagmar Pospisilova; Vladimir Divoky; Monika Horvathova Journal: Int J Mol Sci Date: 2020-12-17 Impact factor: 5.923
Authors: Nahuel A Paolini; Kat S Moore; Franca M di Summa; Ivo F A C Fokkema; Peter A C 't Hoen; Marieke von Lindern Journal: PLoS One Date: 2018-04-10 Impact factor: 3.240